Ranbaxy Launches Soliten for treatment of Urology disorder product introduced for the first time in India

Ranbaxy Laboratories Ltd has announced the launch of its brand Soliten (Solifenacin) in the Indian Markets for the management of chronic urological disorder. The product is being introduced for the first time in India. Soliten will be sold in dosage form of 5 mg and 10 mg tablets.

Soliten is a new and safer formulation that will provide effective relief from chronic problems of Overactive Bladder (OAB) which leads to symptoms such as inability to hold urine coupled with urgency and increased frequency to pass urine. The product is documented to have lesser side effects and greater effectiveness.

Commenting on the launch, Sanjeev I Dani, Regional Director, India & Middle East of the Company said, "An overactive bladder largely remains untreated due to prevailing low awareness amongst its suffers. The introduction of Soliten will strengthen the options available to urologists in treating the symptoms of this highly uncomfortable and annoying medical condition. The Ranbaxy Urology franchise has become a leader in its category in a short span of 3 years since its launch and the introduction of Soliten should help to further consolidated this position.

One out of every eleven individuals in the above 40 age group is believed to suffer from an Overactive Bladder. The problem is equally common in males as well as females and more dominant among the urban population.

Source : Equity Bulls

Keywords